CN1045791A - 使用核苷衍生物的协同组合物抑制人免疫缺陷病毒 - Google Patents

使用核苷衍生物的协同组合物抑制人免疫缺陷病毒 Download PDF

Info

Publication number
CN1045791A
CN1045791A CN90102298A CN90102298A CN1045791A CN 1045791 A CN1045791 A CN 1045791A CN 90102298 A CN90102298 A CN 90102298A CN 90102298 A CN90102298 A CN 90102298A CN 1045791 A CN1045791 A CN 1045791A
Authority
CN
China
Prior art keywords
hiv
dideoxy
nucleoside derivates
ddi
cell
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN90102298A
Other languages
English (en)
Chinese (zh)
Inventor
维拉·布兰可芬
理查德·J·怀特
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Oncogen LP
Original Assignee
Oncogen LP
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Oncogen LP filed Critical Oncogen LP
Publication of CN1045791A publication Critical patent/CN1045791A/zh
Pending legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Molecular Biology (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Virology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
CN90102298A 1989-03-17 1990-03-17 使用核苷衍生物的协同组合物抑制人免疫缺陷病毒 Pending CN1045791A (zh)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US32493489A 1989-03-17 1989-03-17
US324,934 1989-03-17
US40190889A 1989-09-01 1989-09-01
US401,908 1989-09-01

Publications (1)

Publication Number Publication Date
CN1045791A true CN1045791A (zh) 1990-10-03

Family

ID=26984692

Family Applications (1)

Application Number Title Priority Date Filing Date
CN90102298A Pending CN1045791A (zh) 1989-03-17 1990-03-17 使用核苷衍生物的协同组合物抑制人免疫缺陷病毒

Country Status (19)

Country Link
EP (1) EP0464137A4 (xx)
JP (1) JPH04504850A (xx)
KR (1) KR920700653A (xx)
CN (1) CN1045791A (xx)
AU (1) AU5351490A (xx)
CA (1) CA2050473A1 (xx)
DD (1) DD301787A9 (xx)
FI (1) FI914367A0 (xx)
GR (1) GR1000618B (xx)
HU (1) HU208254B (xx)
IL (1) IL93783A0 (xx)
NO (1) NO913659L (xx)
NZ (1) NZ232912A (xx)
OA (1) OA09555A (xx)
PL (1) PL284343A1 (xx)
PT (1) PT93449A (xx)
WO (1) WO1990011081A1 (xx)
YU (1) YU53790A (xx)
ZW (1) ZW3290A1 (xx)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK0513917T4 (da) * 1991-05-16 2001-06-25 Glaxo Group Ltd Antivirale kombinationer indeholdende nukleosidanaloger
CA2335617C (en) * 1998-06-24 2009-12-15 Emory University Use of 3'-azido-2',3'-dideoxyuridine in combination with further anti-hiv drugs for the manufacture of a medicament for the treatment of hiv
AU2002255707A1 (en) 2001-03-15 2002-10-03 Trustees Of Boston College, The Selective anti-viral nucleoside chain terminators

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1987001284A1 (en) * 1985-08-26 1987-03-12 United States Of America, Represented By The Unite Inhibition of in vitro infectivity and cytopathic effect of htlv-iii/lav by 2',3'-dideoxynosine, 2',3'-dideoxyguanosine, or 2',3'-dideoxyadenosine
GB8712115D0 (en) * 1987-05-22 1987-06-24 Hoffmann La Roche Pyrimidine derivatives
US4837311A (en) * 1987-06-22 1989-06-06 Hoffman-La Roche Inc. Anti-retroviral compounds
NZ226672A (en) * 1987-10-30 1991-07-26 Hoffmann La Roche 6-amino-9-(2,3-dideoxy-2-fluoro-b-d-threopentofuranosyl)-9h-purine derivatives and pharmaceutical compositions
US4908440A (en) * 1987-11-12 1990-03-13 Bristol Myers Company 2',3'-dideoxy-2'-fluoroarabinopyrimidine nucleosides

Also Published As

Publication number Publication date
OA09555A (en) 1993-01-31
HUT57988A (en) 1992-01-28
PL284343A1 (en) 1991-06-03
GR1000618B (el) 1992-08-31
NO913659D0 (no) 1991-09-17
EP0464137A1 (en) 1992-01-08
ZW3290A1 (en) 1990-11-07
JPH04504850A (ja) 1992-08-27
CA2050473A1 (en) 1990-09-18
GR900100189A (en) 1990-07-31
YU53790A (sh) 1993-05-28
NO913659L (no) 1991-10-18
FI914367A0 (fi) 1991-09-17
HU208254B (en) 1993-09-28
PT93449A (pt) 1990-11-07
DD301787A9 (de) 1994-01-13
NZ232912A (en) 1992-06-25
KR920700653A (ko) 1992-08-10
AU5351490A (en) 1990-10-22
EP0464137A4 (en) 1992-01-15
IL93783A0 (en) 1990-12-23
WO1990011081A1 (en) 1990-10-04
HU902898D0 (en) 1991-12-30

Similar Documents

Publication Publication Date Title
Mitsuya et al. Inhibition of the in vitro infectivity and cytopathic effect of human T-lymphotrophic virus type III/lymphadenopathy-associated virus (HTLV-III/LAV) by 2', 3'-dideoxynucleosides.
Chinen et al. Molecular virology and immunology of HIV infection
Gosselin et al. Anti-human immunodeficiency virus activities of the beta-L enantiomer of 2', 3'-dideoxycytidine and its 5-fluoro derivative in vitro
Fisher et al. Biologically diverse molecular variants within a single HIV-1 isolate
Sorrentino et al. Selection of drug-resistant bone marrow cells in vivo after retroviral transfer of human MDR 1
JP2656938B2 (ja) ｄｓＲＮＡと逆転写酵素インヒビターを含んで成るＨＩＶ感染治療のための医薬組成物
Balzarini et al. Activity of the (R)-enantiomers of 9-(2-phosphonylmethoxypropyl)-adenine and 9-(2-phosphonylmethoxypropyl)-2, 6-diaminopurine against human immunodeficiency virus in different human cell systems
Mori et al. Restricted replication of simian immunodeficiency virus strain 239 in macrophages is determined by env but is not due to restricted entry
Finnegan et al. IL-10 cooperates with TNF-alpha to activate HIV-1 from latently and acutely infected cells of monocyte/macrophage lineage.
Weiss Retrovirus classification and cell interactions
JPH0125A (ja) ｄｓＲＮＡと逆転写酵素インヒビターを含んで成るＨＩＶ感染治療のための医薬組成物
Broder et al. Antiretroviral therapy in AIDS
Hirsch et al. Treatment of human immunodeficiency virus infections
EP0318281A2 (en) Use of dsRNA in the prevention of viral escape
Vahlenkamp et al. (R)-9-(2-phosphonylmethoxypropyl)-2, 6-diaminopurine is a potent inhibitor of feline immunodeficiency virus infection
Yarchoan et al. Clinical and basic advances in the antiretroviral therapy of human immunodeficiency virus infection
CN1045791A (zh) 使用核苷衍生物的协同组合物抑制人免疫缺陷病毒
Connolly et al. Antiretroviral therapy: strategies beyond single-agent reverse transcriptase inhibition
Vogt et al. Prospects for the prevention and therapy of infections with the human immunodeficiency virus
WO1996011005A2 (en) Use of camptothecin or derivatives thereof for the manufacture of a medicament for the treatment of viral diseases
Hirsch et al. Antiviral therapy
Zeidner et al. Treatment of FeLV-induced immunodeficiency syndrome (FeLV-FAIDS) with controlled release capsular implantation of 2′, 3′-dideoxycytidine
Wainberg et al. Vaccine and antiviral strategies against infections caused by human immunodeficiency virus.
Oxford et al. Potential target sites for antiviral inhibitors of human immunodeficiency virus (HIV)
Ruprecht Murine models for antiretroviral therapy

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
C01 Deemed withdrawal of patent application (patent law 1993)
WD01 Invention patent application deemed withdrawn after publication